La Jolla Pharmaceutical Co. received an approvable letter for its lupus drug candidate Riquent that requires the completion of another clinical study for final approval. (BioWorld Today)
Working to better understand infectious diseases, the University of New Mexico is joining with DeCode Genetics Inc. and the National Center for Genome Resources in a five-year research agreement. (BioWorld Today)
Eight months after receiving approval for Erbitux in colorectal cancer, ImClone Systems Inc. and Bristol-Myers Squibb Co. set out on another Phase III program for the drug, this time targeting non-small-cell lung cancer. (BioWorld Today)
